Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Jan 1;101(1):10–14. doi: 10.1172/JCI781

Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor.

M C Minnema 1, P W Friederich 1, M Levi 1, P A von dem Borne 1, L O Mosnier 1, J C Meijers 1, B J Biemond 1, C E Hack 1, B N Bouma 1, H ten Cate 1
PMCID: PMC508534  PMID: 9421460

Abstract

Recent in vitro studies have shown that fibrinolytic activity may be attenuated by a thrombin-activatable fibrinolysis inhibitor (TAFI), which is activated by thrombin, generated via the intrinsic pathway of coagulation in a factor XI-dependent way. Thus factor XI may play a role in the regulation of endogenous fibrinolysis. The aim of this study was to investigate the effect of in vivo inhibition of factor XI and TAFI in an experimental thrombosis model in rabbits. Incorporation of anti-factor XI antibodies in jugular vein thrombi resulted in an almost twofold increase in endogenous thrombolysis compared with a control antibody. A similar effect was observed when the anti-factor XI antibody was administered systemically. Inhibition of TAFI activity also resulted in a twofold increase in clot lysis whereas inhibition of both factor XI and TAFI activity had no additional effect. Thus, we provide the first in vivo evidence for enhanced thrombolysis through inhibition of clotting factor XI, demonstrating a novel role for the intrinsic pathway of coagulation. Furthermore we demonstrate that inhibition of TAFI had a similar effect on thrombolysis. We postulate that inhibition of factor XI activity enhances thrombolysis because of diminished indirect activation of TAFI.

Full Text

The Full Text of this article is available as a PDF (171.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asakai R., Chung D. W., Davie E. W., Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med. 1991 Jul 18;325(3):153–158. doi: 10.1056/NEJM199107183250303. [DOI] [PubMed] [Google Scholar]
  2. Bajzar L., Manuel R., Nesheim M. E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995 Jun 16;270(24):14477–14484. doi: 10.1074/jbc.270.24.14477. [DOI] [PubMed] [Google Scholar]
  3. Bajzar L., Morser J., Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996 Jul 12;271(28):16603–16608. doi: 10.1074/jbc.271.28.16603. [DOI] [PubMed] [Google Scholar]
  4. Berliner S., Horowitz I., Martinowitz U., Brenner B., Seligsohn U. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinolysis. 1992 Aug;3(4):465–468. [PubMed] [Google Scholar]
  5. Biemond B. J., Friederich P. W., Levi M., Vlasuk G. P., Büller H. R., ten Cate J. W. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation. 1996 Jan 1;93(1):153–160. doi: 10.1161/01.cir.93.1.153. [DOI] [PubMed] [Google Scholar]
  6. De La Cadena R. A., Baglia F. A., Johnson C. A., Wenk R. E., Amernick R., Walsh P. N., Colman R. W. Naturally occurring human antibodies against two distinct functional domains in the heavy chain of FXI/FXIa. Blood. 1988 Nov;72(5):1748–1754. [PubMed] [Google Scholar]
  7. Derkx F. H., Bouma B. N., Schalekamp M. P., Schalekamp M. A. An intrinsic factor XII- prekallikrein-dependent pathway activates the human plasma renin-angiotensin system. Nature. 1979 Jul 26;280(5720):315–316. doi: 10.1038/280315a0. [DOI] [PubMed] [Google Scholar]
  8. Kaplan A. P., Silverberg M. The coagulation-kinin pathway of human plasma. Blood. 1987 Jul;70(1):1–15. [PubMed] [Google Scholar]
  9. Kumar R., Béguin S., Hemker H. C. The influence of fibrinogen and fibrin on thrombin generation--evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost. 1994 Nov;72(5):713–721. [PubMed] [Google Scholar]
  10. Nemerson Y. Tissue factor and hemostasis. Blood. 1988 Jan;71(1):1–8. [PubMed] [Google Scholar]
  11. PROCTOR R. R., RAPAPORT S. I. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol. 1961 Sep;36:212–219. doi: 10.1093/ajcp/36.3.212. [DOI] [PubMed] [Google Scholar]
  12. Ragni M. V., Sinha D., Seaman F., Lewis J. H., Spero J. A., Walsh P. N. Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood. 1985 Mar;65(3):719–724. [PubMed] [Google Scholar]
  13. Rapaport S. I., Rao L. V. The tissue factor pathway: how it has become a "prima ballerina". Thromb Haemost. 1995 Jul;74(1):7–17. [PubMed] [Google Scholar]
  14. Redlitz A., Tan A. K., Eaton D. L., Plow E. F. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest. 1995 Nov;96(5):2534–2538. doi: 10.1172/JCI118315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sakharov D. V., Plow E. F., Rijken D. C. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem. 1997 May 30;272(22):14477–14482. doi: 10.1074/jbc.272.22.14477. [DOI] [PubMed] [Google Scholar]
  16. Seligsohn U. Factor XI deficiency. Thromb Haemost. 1993 Jul 1;70(1):68–71. [PubMed] [Google Scholar]
  17. Tan A. K., Eaton D. L. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry. 1995 May 2;34(17):5811–5816. doi: 10.1021/bi00017a012. [DOI] [PubMed] [Google Scholar]
  18. Von dem Borne P. A., Bajzar L., Meijers J. C., Nesheim M. E., Bouma B. N. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest. 1997 May 15;99(10):2323–2327. doi: 10.1172/JCI119412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Warn-Cramer B. J., Rapaport S. I. Evidence suggestive of activation of the intrinsic pathway of blood coagulation after injection of factor Xa/phospholipid into rabbits. Arterioscler Thromb Vasc Biol. 1995 Jan;15(1):133–139. doi: 10.1161/01.atv.15.1.133. [DOI] [PubMed] [Google Scholar]
  20. Weitz J. I., Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990 Aug;86(2):385–391. doi: 10.1172/JCI114723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wiggins R. C., Cochrane C. G., Griffin J. H. Rabbit blood coagulation factor XI. Purification and properties. Thromb Res. 1979;15(3-4):475–486. doi: 10.1016/0049-3848(79)90153-1. [DOI] [PubMed] [Google Scholar]
  22. ten Cate H., Biemond B. J., Levi M., Wuillemin W. A., Bauer K. A., Barzegar S., Buller H. R., Hack C. E., ten Cate J. W., Rosenberg R. D. Factor XIa induced activation of the intrinsic cascade in vivo. Thromb Haemost. 1996 Mar;75(3):445–449. [PubMed] [Google Scholar]
  23. von dem Borne P. A., Meijers J. C., Bouma B. N. Effect of heparin on the activation of factor XI by fibrin-bound thrombin. Thromb Haemost. 1996 Sep;76(3):347–353. [PubMed] [Google Scholar]
  24. von dem Borne P. A., Meijers J. C., Bouma B. N. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood. 1995 Oct 15;86(8):3035–3042. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES